Regulatory affairs converts science into approvals: the submission dossiers, agency interactions, clinical trial regulations compliance, labeling, and post-market obligations that stand between a product and its market. The discipline spans pharmaceutical regulatory affairs, medical device regulatory affairs, regulatory strategy, and the pharmacovigilance and quality systems that run after launch. Its practitioners are defined by which regulation they argue under and which authority they face.
The profession is small and the demand clock is loud. The RAPS workforce report, built with Elemed, sizes the global regulatory affairs profession at nearly 125,000 professionals . CDER approved 46 novel drugs in 2025, and issued 19 complete response letters for 18 novel drugs along the way . Every one of those filings, approvals and rejections was carried by the same small workforce, which is the entire shape of this hiring market.
Challenges in Regulatory Affairs Recruiting
Pharmaceutical regulatory affairs bench is small and credentialed
The workforce data quantifies the scarcity. RAPS and Elemed counted nearly 125,000 regulatory affairs professionals worldwide in their second workforce report, spread across pharmaceuticals, devices and biologics . Credentialing shows how shallow the senior layer is: RAPS ended 2025 with more than 30,000 members and awarded 390 Regulatory Affairs Certification credentials during the year, joining the more than 4,500 professionals who hold a current RAC globally . The society launched its entry-level Foundation in Regulatory Affairs credential in May 2025, a direct response to employers reporting that even junior pipelines are thin .
The profession has no feeder school. Regulatory knowledge accretes through submissions, inspections and agency meetings, each of which takes years to accumulate and none of which can be taught in a degree program. The RAPS competency framework exists precisely because the skill set is acquired, not taught, and it maps the profession across levels that employers struggle to fill from the outside . Employers competing for the credentialed few are bidding on a population that barely grows, and internal promotion is slow because the work cannot be safely delegated to people who have not seen a review cycle fail.
Drug approvals set the demand clock with every complete response letter
The filing calendar is the discipline's operating rhythm. CDER's 2025 approvals report counts 46 novel drugs, 20 of them first-in-class and 23 orphan-designated, while the center also issued 19 complete response letters for 18 novel drugs whose applications did not meet statutory requirements . Each letter returns a filing to its sponsor with a defined resubmission window, and each refiling consumes regulatory strategy capacity that was already allocated to the next program.
The consequence for hiring is precise. Regulatory strategy experience is measured in agency interactions survived: pre-IND and end-of-phase meetings, breakthrough designations negotiated, deficiencies answered. A team staffing a pivotal-year program needs people who have carried that exact load, and the population that has is proportional to the number of successful filings, not to the number of companies. Delays concentrate demand further, because every CR letter keeps a strategist occupied on a program they expected to close, and the replacement market shrinks exactly when the workload spikes.
Medical device regulatory affairs runs on a different evidence rulebook
The device side is not a pharma specialty. Device regulatory affairs lives on design controls, risk management files, clinical evaluation and the 510(k), De Novo and PMA pathways, with quality systems obligations that reach into every engineering team. The credentialing split formalizes the divide: RAC comes in Drugs and Devices designations, and the society's new compliance certification validates European device and IVD regulations specifically .
Crossing the line is rarer than job descriptions assume. A pharmaceutical submissions manager who has never owned a design history file or answered a notified body cannot run an MDR technical documentation program, and a device specialist cannot step into a BLA. Companies that treat regulatory affairs as one function hire the wrong specialist and discover it at the first reviewer question. The two populations also sit in different employers, device manufacturers versus pharma and biotech, so sourcing has to name the regulation to reach the right bench. The gap runs through adjacent seats too: a combination product, part device and part drug, needs both rulebooks in one filing team, and those hybrid specialists are among the scarcest people in the profession.
Clinical trial regulations rewrote GCP in 2025
ICH finalized E6(R3) Good Clinical Practice in January 2025, the first full revision of the GCP guideline in decades . The new structure reframes trial conduct around proportionate risk-based approaches, data governance and technology, and every sponsor, CRO and site in the harmonized world is now aligning SOPs, monitoring plans and documentation against it .
For hiring, the revision is a boundary line. The pool of people who have actually operated a study under E6(R3) is younger than the industry's experience curve, and much of the most senior GCP expertise was built under a guideline that has changed under it. A candidate who can describe how their last protocol handled the new data governance expectations is worth a different salary than one whose GCP knowledge predates the revision. This is one of the few moments in regulatory affairs where freshness beats tenure.
Quality systems turn dossiers into living documents
Approval is not the end of the regulatory obligation. Post-market responsibilities run through GMP-based quality systems, pharmacovigilance and periodic reporting, and ICH Q10 frames the pharmaceutical quality system as the continuous structure under all of it, connecting development knowledge to manufacturing and to product life-cycle management . For drugs, safety obligations continue in signal detection, periodic safety update reports and risk management plans; for devices, in post-market surveillance and vigilance reporting.
The scarce profile here is the person who can own the living document. Quality system auditors and pharmacovigilance specialists who have run inspections, answered 483 observations, or managed a signal through a labeling change carry experience that a submission-only team cannot summon. Their hiring signal is not credentials but a history of post-approval events handled without escalation, which is exactly what a CV least often states explicitly. The same living-document logic now extends to submissions themselves: electronic common technical document authoring, structured product labeling and regulatory information management systems have turned the dossier into a maintained data asset, and operations specialists who run those systems are hired on the same scarcity curve.
Regulatory submissions claims collapse under the sections they authored
Verification in regulatory affairs is documentary by nature, and that makes it testable. Ask a strategist which module sections they personally wrote, which agency meetings they led, and what the regulator asked for afterward. Ask a device specialist which design history file elements they signed and which notified body findings they answered. Ask a pharmacovigilance candidate which signal they escalated and what changed in the label. The answers either name documents, timelines and outcomes, or they dissolve into process vocabulary.
The cost of a miss is the complete response letter. A weak hire in this seat does not produce a quiet underperformance; they produce a rejected filing, a resubmission against the PDUFA clock, and a launch delay that multiplies across the commercial organization . In a discipline where every decision is on the record, the interview that does not read the record is hiring blind.
References
- New Report Showcases a Global Regulatory Affairs Workforce of Nearly 125,000 Professionals Across the Healthcare Products Sector — Regulatory Affairs Professionals Society (RAPS). (accessed 2026-09-28)
- RAPS 2025 Year in Review — Regulatory Affairs Professionals Society (RAPS). (accessed 2026-09-28)
- Advancing Health Through Innovation: New Drug Therapy Approvals 2025 — U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). (accessed 2026-09-28)
- ICH Harmonised Guideline E6(R3): Good Clinical Practice — International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (accessed 2026-09-28)
- ICH Quality Guidelines (including Q10 Pharmaceutical Quality System) — International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (accessed 2026-09-28)